Raymond James Financial Services Advisors’s State Street SPDR S&P Pharmaceuticals ETF XPH Stock Holding History

Raymond James Financial Services Advisors’s Portfolio XPH Stock Details XPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-5,578	Closed	-$222K	–	3438
2023 Q3	$222K	Sell	5,578 -17	-0.3%	-$719	﹤0.01%	2866
2023 Q2	$229K	Sell	5,595 -200	-3%	-$8.26K	﹤0.01%	2834
2023 Q1	$238K	Buy	5,795 +181	+3%	+$7.61K	﹤0.01%	2787
2022 Q4	$230K	Sell	5,614 -331,400	-98%	-$13.8M	﹤0.01%	2772
2022 Q3	$13.5M	Buy	337,014 +331,254	+5,751%	+$14.2M	0.03%	511
2022 Q2	$242K	Sell	5,760 -811	-12%	-$34K	﹤0.01%	2751
2022 Q1	$298K	Buy	6,571 +238	+4%	+$10.5K	﹤0.01%	2720
2021 Q4	$292K	Buy	6,333 +284	+5%	+$13.5K	﹤0.01%	2730
2021 Q3	$287K	Buy	6,049 +391	+7%	+$19.4K	﹤0.01%	2721
2021 Q2	$293K	Buy	5,658 +74	+1%	+$3.71K	﹤0.01%	2742
2021 Q1	$281K	Sell	5,584 -485	-8%	-$25.9K	﹤0.01%	2667
2020 Q4	$316K	Buy	6,069 +1,261	+26%	+$60.3K	﹤0.01%	2432
2020 Q3	$209K	Buy	+4,808	New	+$211K	﹤0.01%	2518
2018 Q4	–	Sell	-4,302	Closed	-$209K	–	2861
2018 Q3	$209K	Buy	+4,302	New	+$204K	﹤0.01%	2503
2018 Q2	–	Sell	-5,665	Closed	-$237K	–	2865
2018 Q1	$237K	Sell	5,665 -221	-4%	-$9.63K	﹤0.01%	2157
2017 Q4	$256K	Sell	5,886 -7,211	-55%	-$307K	﹤0.01%	2105
2017 Q3	$557K	Sell	13,097 -1,317	-9%	-$55.8K	﹤0.01%	1652
2017 Q2	$620K	Buy	14,414 +43	+0.3%	+$1.81K	﹤0.01%	1558
2017 Q1	$601K	Sell	14,371 -49	-0.3%	-$2K	﹤0.01%	1470
2016 Q4	$564K	Sell	14,420 -22,168	-61%	-$902K	﹤0.01%	1465
2016 Q3	$1.62M	Sell	36,588 -1,369	-4%	-$62.2K	0.01%	853
2016 Q2	$1.59M	Sell	37,957 -3,365	-8%	-$143K	0.02%	840
2016 Q1	$1.66M	Sell	41,322 -1,592	-4%	-$67.4K	0.02%	698
2015 Q4	$2.2M	Buy	42,914 +3,555	+9%	+$181K	0.03%	611
2015 Q3	$1.85M	Buy	39,359 +13,743	+54%	+$828K	0.03%	551
2015 Q2	$1.6M	Buy	+25,616	New	+$1.6M	0.11%	237
2013 Q3	–	Sell	-34,190	Closed	-$1.21M	–	963
2013 Q2	$1.21M	Buy	+34,190	New	+$1.15M	0.04%	552

Other funds holding XPH

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

FCBT

First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return

Envestnet Portfolio Solutions Chicago, Illinois $20.9B AUM 19.34% 1-Year Est. Return

Raymond James Financial Services Advisors's XPH Position: Q4 2023 in Review

Raymond James Financial Services Advisors sold out of State Street SPDR S&P Pharmaceuticals ETF (XPH) in Q4 2023, closing a stake of 5,578 shares — an estimated $222K sold.

Raymond James Financial Services Advisors first reported a position in XPH in Q2 2013 and held it in 27 quarters. The position peaked at $13.5M in Q3 2022. 73 funds tracked by Wall St. Rank hold XPH as of Q4 2023.

Raymond James Financial Services Advisors reported no remaining State Street SPDR S&P Pharmaceuticals ETF position as of Q4 2023 after selling out during the quarter.
Raymond James Financial Services Advisors sold 5,578 State Street SPDR S&P Pharmaceuticals ETF shares in Q4 2023, an estimated $222K.
Raymond James Financial Services Advisors first reported a position in State Street SPDR S&P Pharmaceuticals ETF in Q2 2013 and held it in 27 quarters.
Raymond James Financial Services Advisors's State Street SPDR S&P Pharmaceuticals ETF position peaked at $13.5M in Q3 2022.
73 funds tracked by Wall St. Rank held State Street SPDR S&P Pharmaceuticals ETF as of Q4 2023.

Based on Raymond James Financial Services Advisors's 13F filing for Q4 2023, filed 16 Jan 2024.